



November 13, 2020

To,

Manager (CDR)
Bombay Stock Exchange Limited (BSE)
P.J. Towers, Dalal Street,
Mumbai-400001.

Ref: DR LALCHANDANI LABS LIMITED (Scrip Code: 541299)

Subject: Outcome of the Board Meeting dated 13.11.2020

Dear Sir/ Madam,

Please find enclosed herewith Unaudited Financial Results for the half year ended on September 30, 2020 along with Limited Review Report approved by the Board of Directors of the Company at its meeting held today i.e. November 13, 2020 in terms of Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

It is also intimated that the date of re-opening of trading window will be as per the following details:

Closure of Trading Window from	Closure of Trading Window till	Purpose of closure of trading window
01/10/2020	15/11/2020	Declaration of Un-Audited Financial Results for the half year ended September 30, 2020.

The said meeting of the Board of Directors commenced at 04.00 p.m. and concluded at 07.30 p.m.

Please take the same on your record.

Thanking You,

Yours Faithfully,

For DR LALCHANDANI LABS LIMITED



Arjan Lalchandani
Managing Director
DIN: 07014579

Encl: As Above



DR LALCHANDANI LABS LIMITED

(CIN: L85320DL2017PLC321605)

Regd. Office: M-20 Basement, Greater Kailash-1, New Delhi -110048.

Website: <http://lalchandaniplab.com/>, Email id: info@lalchandaniplab.com

Phone: 8010689689/ 8010998844

UN-AUDITED STANDALONE FINANCIAL RESULTS FOR THE HALF YEAR ENDED SEPTEMBER 30, 2020

Amount Rs. in Lacs

Sr. No.	Particulars	Half Year Ended			For the Year Ended	Previous Year Ended
		30.09.2020	31.03.2020	30.09.2019	31.03.2020	31.03.2019
		Un-audited	Audited	Un-audited	Audited	Audited
I	Revenue from Operations	271.30	306.96	303.43	610.39	526.10
II	Other Income			-	-	0.57
III	Total Revenue (I+II)	271.30	306.96	303.43	610.39	526.67
IV	Expenses					
	(a) Cost of materials consumed	104.10	63.42	51.20	114.62	60.57
	(b) Employee benefits expense	32.92	41.94	44.27	86.21	94.59
	(c) Finance Cost	5.27	9.29	9.21	18.50	13.63
	(d) Depreciation and amortisation expense	22.82	21.76	20.54	42.30	34.89
	(e) Other Expenses	76.95	147.58	135.10	282.68	251.09
	Total Expenses	242.05	283.99	260.32	544.30	454.77
V	Profit before exceptional and extraordinary items and tax (III - IV)	29.25	22.97	43.11	66.08	71.90
VI	Exceptional Items				-	
VII	Profit extraordinary items and tax (V - VI)	29.25	22.97	43.11	66.08	71.90
VIII	Extraordinary Items				-	
IX	Profit before tax (VIII - IX)	29.25	22.97	43.11	66.08	71.90
X	Tax Expenses:				-	
	(1) Current Tax	6.69	15.81	-	15.81	15.77
	(2) Deferred Tax	-	2.84	-	2.84	2.78
XI	Profit / (Loss) from Period from continuing operations (VII -VIII)	22.56	4.32	43.11	47.43	53.35
XII	Profit (Loss) from discontinuing Operations	-	-	-	-	-
XIII	Tax Expense of Discontinuing operations	-	-	-	-	-
XIV	Profit / (Loss) from Discontinuing operations (After Tax XII- XIII)	-	-	-	-	-
XV	Profit (Loss) for the period (XI +XIV)	22.56	4.32	43.11	47.43	53.35
XVI	Earnings Per Share of Rs. 10 Each (Not Annualised)					
	(a) Basic (Rs.)	0.52	0.10	0.99	1.09	1.23
	(b) Diluted (Rs.)	0.52	0.10	0.99	1.09	1.23

Notes:

- The financial results were reviewed by the audit committee and approved by the Board of directors at its meeting held on 13-11-2020.
- There were no investor complaints received / pending as at 30th September 2020.
- The company does not have more than one reportable segment in terms of AS-17 issued by ICAI. Hence segment wise reporting is not applicable.
- The figures for the corresponding previous period have been regrouped/ reclassified wherever considered necessary.
- On March 11, 2020, the World Health Organization declared COVID-19 a global pandemic and suggested guidelines for containment and mitigation worldwide. This has impacted the operations of the Company during the half year ended September 30, 2020. As at September 30, 2020, the Management has used Internal and external sources of information upto the date of approval of these financial results in determining the impact of the COVID-19 pandemic.

The Management has used the principles of prudence in developing estimates, assumptions, exercising judgements and performing sensitivity analysis. The eventual outcome of the impact of the pandemic may be different from that estimated as on the date of approval of these financial results. However, the impact assessment of COVID-19 is a continuous process, given the uncertainties associated with its nature and duration. The Company will continue to monitor any material changes to future economic conditions and the consequent impact on its business, If any, and any significant impact of these changes would be recognized in the financial results as and when these material changes to economic conditions arise.

For Dr Lalchandani Labs Limited,



(Dr. Arjan Lalchandani)

Managing Director (DIN: 07014579)

New Delhi

13-Nov-2020

DR LALCHANDANI LABS LIMITED

(CIN: L85320DL2017PLC321605)

Regd. Office: M-20 Basement, Greater Kailash-1, New Delhi -110048.

Website: <http://lalchandaniplab.com/>, Email id: info@lalchandaniplab.com

Phone: 8010689689/ 8010998844

STANDALONE STATEMENT OF ASSETS AND LIABILITIES*Amount in Rs. Lacs*

Sr. No.	Particulars	For the Year Ended	
		30-09-2020	31-03-2020
1	Shareholders' Funds		
	(a) Share Capital	433.31	433.31
	(b) Reserves and Surplus	443.32	420.76
	(c) Money received against share warrants	-	-
	Sub-total-Shareholders' Funds	876.62	854.07
2	Share application money pending allotment		
3	Non- Current Liabilities		
	(a) Long Term Borrowings	226.45	170.85
	(b) Deferred Tax Liability	8.01	8.01
	(c) Other Long Term Liabilities	-	-
	(d) Long Term Provisions	-	-
	Sub-total-Non Current Liabilities	234.46	178.86
4	Current Liabilities		
	(a) Short Term Borrowings	5.30	5.01
	(b) Trade Payables	101.57	112.36
	(c) Other Current Liabilities	33.53	27.31
	(d) Short Term Provisions	22.51	15.81
	Sub-total-Current Liabilities	162.91	160.49
	TOTAL EQUITY AND LIABILITIES	1,273.99	1,193.42
II	ASSETS		
1	Non-Current Assets		
	(a) Fixed Assets		
	(i) Tangible assets	373.83	331.63
	(ii) Intangible assets	13.37	15.49
	(b) Non-Current Investments	24.10	24.10
	(c) Long Term Loans & Advances	31.75	31.75
	(d) Other Non-Current Assets	34.30	34.30
	Sub-total-Non Current Assets	477.35	437.26
2	Current Assets		
	(a) Current Investments	-	-
	(b) Inventories	51.05	49.70
	(c) Trade Receivables	390.24	332.75
	(d) Cash & cash equivalents	208.88	225.28
	(e) Short Term Loans & Advances	106.61	106.17
	(f) Other Current Assets	39.86	42.26
	Sub-total-Current Assets	796.64	756.16
	TOTAL ASSETS	1,273.99	1,193.42

For Dr Lalchandani Labs Limited



Dr. Arjan Lalchandani
 (Managing Director DIN: 07014579)

New Delhi

13-Nov-2020

Cash Flow Statement for the Half-Year Ended 30.09.20

	<u>Particulars</u>	<u>Amount</u>
A	<u>Cash Flow From Operating Activities</u>	
	Net Profit/(Loss) Before Tax	29.25
	Adjustment For:	
	Depreciation	22.82
	Interest Expense	4.76
	<u>Operating Profit Before Working Capital Changes</u>	27.59
		56.84
	 <u>Changes in Working Capital</u>	
	Change in Sundry Debtors	(57.48)
	Change in Other Current Assets & Non Current Assets	2.39
	Change in Trade Payables	(10.80)
	Changes in Inventories	(1.35)
	Change in Other Current Liabilities	6.22
	<u>Net Cash Flows From Operating Activities(A)</u>	(61.02)
		(4.18)
B	<u>Cash Flow From Investing Activities</u>	
	Purchase of Fixed Assets	(62.91)
	Loans and Advances given	(0.44)
	<u>Net Cash Flow From Investing Activities (B)</u>	(63.35)
C	<u>Cash Flow From Financing Activities</u>	
	Long Term Borrowings taken	55.89
	Interest Paid	(4.76)
	<u>Net Cash Flow From Financing Activities (C)</u>	51.13
	 <u>Net Change in Cash (A+B+C)</u>	(16.40)
	Cash and Cash Equivalents at the Beginning of Year	225.28
	Cash and Cash Equivalents at the End of Year	208.88

For Dr Lalchandani Labs Limited



Dr. Arjan Lalchandani
(Managing Director DIN: 07014579)

New Delhi

13-Nov-2020



Jain Agarwal & Company

Chartered Accountants

LIMITED REVIEW REPORT

TO

**THE BOARD OF DIRECTORS OF
DR LALCHANDANI LABS LIMITED**

We have reviewed the accompanying statement of unaudited financial results of Dr Lalchandani Labs Limited ("the Company") for the half year ended 30th September, 2020 ("the statement"). This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Jain Agarwal and Company
Chartered Accountants
Firm's Registration No.: 024866N



CA Karan Jain
(Partner)
Membership No.: 521992

Place: New Delhi
Date: 13th November, 2020
UDIN No.: 20521992AAAABK3795